ENDPOINTS

Enliven stops work on solid tumor drug; Pulmatrix to divest assets

May 15, 2025 - 15:54
 0
Enliven stops work on solid tumor drug; Pulmatrix to divest assets
Read More

Tags:

Previous Article

Companies behind dairy industry’s first methane targets show early success

Next Article

Pathos AI collects $365M to fuel data-driven oncology studies

Related Posts

NewAmsterdam's pooled Phase 3 data; C4 seeks partners for solid tumor degrader

NewAmsterdam's pooled Phase 3 data; C4 seeks partners f...

May 7, 2025  0

Philadelphia doctors treat infant with first custom CRISPR therapy that fixes genetic mutation

Philadelphia doctors treat infant with first custom CRI...

May 15, 2025  0

Where to Buy Quality Used Acura Engines in Florida

May 12, 2025  0